Next Article in Journal
Oncogenic Activation of Nrf2, Though as a Master Antioxidant Transcription Factor, Liberated by Specific Knockout of the Full-Length Nrf1α that Acts as a Dominant Tumor Repressor
Next Article in Special Issue
Glioblastoma: Microenvironment and Niche Concept
Previous Article in Journal
RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective
Previous Article in Special Issue
Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
Open AccessArticle

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma

Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane 4072, Australia
Commonwealth Scientific and Industrial Research Organisation (CSIRO), Brisbane 4006, Australia
Centre for Advanced Imaging, The University of Queensland, Brisbane 4072, Australia
Kenneth G. Jamieson Department of Neurosurgery, Royal Brisbane and Women’s Hospital, Brisbane 4029, Australia
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4059, Australia
Author to whom correspondence should be addressed.
These authors contributed equally to the manuscript.
Co-Senior authors.
Cancers 2018, 10(12), 519;
Received: 13 November 2018 / Revised: 3 December 2018 / Accepted: 11 December 2018 / Published: 17 December 2018
(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
The EphA3 receptor has recently emerged as a functional tumour-specific therapeutic target in glioblastoma (GBM). EphA3 is significantly elevated in recurrent disease, is most highly expressed on glioma stem cells (GSCs), and has a functional role in maintaining self-renewal and tumourigenesis. An unlabelled EphA3-targeting therapeutic antibody is currently under clinical assessment in recurrent GBM patients. In this study, we assessed the efficacy of EphA3 antibody drug conjugate (ADC) and radioimmunotherapy (RIT) approaches using orthotopic animal xenograft models. Brain uptake studies, using positron emission tomography/computed tomography (PET/CT) imaging, show EphA3 antibodies are effectively delivered across the blood-tumour barrier and accumulate at the tumour site with no observed normal brain reactivity. A robust anti-tumour response, with no toxicity, was observed using EphA3, ADC, and RIT approaches, leading to a significant increase in overall survival. Our current research provides evidence that GBM patients may benefit from pay-loaded EphA3 antibody therapies. View Full-Text
Keywords: EphA3; antibody drug conjugate; radioimmunotherapy; glioblastoma; stem cells EphA3; antibody drug conjugate; radioimmunotherapy; glioblastoma; stem cells
Show Figures

Figure 1

MDPI and ACS Style

Offenhäuser, C.; Al-Ejeh, F.; Puttick, S.; Ensbey, K.S.; Bruce, Z.C.; Jamieson, P.R.; Smith, F.M.; Stringer, B.W.; Carrington, B.; Fuchs, A.V.; Bell, C.A.; Jeffree, R.; Rose, S.; Thurecht, K.J.; Boyd, A.W.; Day, B.W. EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers 2018, 10, 519.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop